

EXHIBIT 1

FIG. 54




EXHIBIT 2

FIG. 55 A




EXHIBIT 3

FIG. 55 B




EXHIBIT 4

FIG. 57




EXHIBIT 5






FIGURE 65

EXHIBIT 6

A)



B)




Figure 66

EXHIBIT 7






Figure 67

EXHIBIT 8

A)



B)





Figure 68

EXHIBIT 9

A)



B)




Figure 69

EXHIBIT 10





Figure 70

EXHIBIT 11

PSCA 3C5 MAb Localizes within LAPC9AD Xenograft Tissue

3C5 Treated



mIgG Treated





Figure 71

EXHIBIT 12

3C5 Anti-PSCA MAb is Localized to Established LAPC-9 Tumors




Western blot developed with α -mIgG/K

Figure 72

EXHIBIT 13

SPECIFIC TARGETING OF THE 1G8 ANTI-PSCA MAb TO ESTABLISHED LAPC-9 TUMORS



Method: Mice bearing established LAPC-9 tumors ($>100 \text{ mm}^3$) were injected with either mIgG or the anti-PSCA MAb 1G8. Tumors were harvested a week later and made into protein lysates for Western analysis.

Figure 73